| Overview of PH Prognosis |
Functional Classification of PH
| Markers for Prognosis of PH |
Personal Stories of Prognosis of PH
Early diagnosis and treatment substantially improves the prognosis for pulmonary hypertension associated with systemic sclerosis (scleroderma). (Also see Types of Scleroderma, PH Diagnosis, PH Treatments and Types of Scleroderma: Prognosis and Mortality)
Survival protection by bodyweight in isolated scleroderma–related pulmonary artery hypertension. The results suggest body mass index decline should be contrasted, lung diffusion is useful for screening and with stroke volume index and mixed venous saturation for assessing prognosis and treatment. PubMed, Intern Emerg Med, 04/06/2016.
Sex disparities in systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH): a cohort study. Sex disparities appear to exist in the frequency of PAH, time to PAH diagnosis, PAH disease duration and SSc disease burden. PubMed, Arthritis Res Ther, 2016 Jan 27;18(1):30.
Long-term survival of patients with pulmonary arterial hypertension (PAH). Patients with PAH who achieve recovery to WHO-FC I or II without use of intravenous epoprostenol have similar survival to those who reach the same WHO-FC with use of intravenous epoprostenol. BMC Research Notes, June 2014; 7: 359. (Also see Pulmonary Hypertension Treatments)
Pulmonary Hypertension (PH) Surveillance. Continued surveillance helps us understand and address the evolving trends in hospitalization and mortality associated with PH and PH-associated conditions, especially regarding sex, age, and race/ethnicity disparities. Chest, 2014;146(2):476-495.
Prediction of pulmonary complications and long term survival in systemic sclerosis (SSc). This study provides data on long-term outcome of SSc and the timing and frequency of major organ complications. PubMed, Arthritis Rheumatol, 03/03/2014. (Also see Pulmonary Involvement
Functional Classification of Severe Pulmonary Hypertension. The higher the class the more severe the disease and the greater the urgency for the patient to be accurately diagnosed and started on therapy for pulmonary hypertension. Pulmonary Hypertension RN.
Aberrant immune response with consequent vascular and connective tissue remodeling – causal to scleroderma and associated syndromes? Therapeutic helminth infection or treatment with parasite–derived response modifiers could be promising new management tools for autoimmune connective tissue diseases. PubMed, Curr Opin Rheumatol, 2016 Nov;28(6):571-6.
The role of asymmetric dimethylarginine (ADMA) alone and in combination with N–terminal pro–B–type natriuretic peptide as a screening biomarker for systemic sclerosis–related pulmonary arterial hypertension (SSc–PAH): A case control study. In this small study, use of ADMA in combination with NT–proBNP produced excellent sensitivity and specificity for the non–invasive identification of SSc–PAH. PubMed, Clin Exp Rheumatol, 05/23/2016.
Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension (PAH). With the advent of evidence-based therapies, including newer agents such as macitentan, riociguat and selexipag, the establishment of centres with expertise in PAH and the focus on early detection, there has been considerable improvement in survival. PubMed, Intern Med J, 2015 Mar;45(3):248-54. (Also see Prognosis and Mortality)
Pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) in patients with functional class II dyspnoea: mild symptoms but severe outcome. A majority of patients with mildly symptomatic SSc-PAH in New York Heart Association (NYHA) functional class (FC) II at diagnosis have a severe disease with poor prognosis. Eric Hachulla. Rheumatology. February 8, 2010.
Syl: Systemic Scleroderma/CREST/Pulmonary Hypertension/Sjögren's The physician's assistant noticed that my hands went really blue…
Tony B: Systemic Scleroderma with Pulmonary Fibrosis, Pulmonary Hypertension and Raynaud's It has taken me some time to come to terms with this disease…
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email firstname.lastname@example.org to request our Welcome email, or to report bad links or to update this page content.